National Center for Toxicological Research (NCTR), US Food and Drug Administration, Jefferson, AR 72079, USA.
School of Public Health, Qingdao University, Qingdao, China.
Biochem Pharmacol. 2019 Nov;169:113638. doi: 10.1016/j.bcp.2019.113638. Epub 2019 Sep 10.
Accumulating evidence has demonstrated that genome-derived noncoding RNAs (ncRNAs) play important roles in modulating inter-individual variations observed in drug metabolism and disposition by controlling the expression of genes coding drug metabolizing enzymes and transporters (DMETs) and relevant nuclear receptors (NRs). With the understanding of novel ncRNA regulatory mechanisms and significance in the control of disease initiation and progression, RNA-based therapies are under active investigation that may expand the druggable targets from conventional proteins to RNAs and the genome for the treatment of human diseases. Herein we provide an overview of research strategies, approaches and their limitations in biochemical and pharmacological studies pertaining to ncRNA functions in the regulation of drug and nutrient metabolism and disposition, and discussion on the promise and challenges in developing RNA therapeutics.
越来越多的证据表明,基因组衍生的非编码 RNA(ncRNA)通过控制编码药物代谢酶和转运体(DMETs)和相关核受体(NRs)的基因的表达,在调节药物代谢和处置中观察到的个体间差异方面发挥着重要作用。随着对新型 ncRNA 调控机制及其在疾病发生和发展控制中的意义的认识,RNA 疗法正在积极研究中,这可能将可治疗的靶标从传统蛋白质扩展到 RNA 和基因组,以治疗人类疾病。本文概述了生化和药理学研究中关于 ncRNA 在药物和营养代谢和处置调节中的功能的研究策略、方法及其局限性,并讨论了开发 RNA 疗法的前景和挑战。